TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20088810

Group type: EXPERIMENTAL
Intervention: 900mg/d algal DHA
Number of subjects: 485
Study: 17550787

Group type: EXPERIMENTAL
Intervention: quetiapine monotherapy (n=19)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: quetiapine add-on therapy (n=22)
Number of subjects: 41
Study: 15931573

Group type: EXPERIMENTAL
Intervention: Pterocarpus marsupium extract (PM extract) 450 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pterostilbene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pterocarpus marsupium extract (PM extract)
Number of subjects: 0
Study: 12929273

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg via a 15-minute infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamidronate (90 mg via a two-hour infusion)
Number of subjects: 0
Study: 10780795

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 8842930

Group type: EXPERIMENTAL
Intervention: Geriatrics-focused acute medicine inpatient rotation with a geriatrics-trained internist attending (n = 44)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Geriatrics-focused acute medicine inpatient rotation with a non-geriatrics-trained internist attending (n = 25)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No exposure to the intervention (n = 24)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 93
Study: 1530836

Group type: COMPARATOR
Intervention: 40 micrograms ipratropium bromide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 200 micrograms fenoterol hydrobromide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of 40 micrograms ipratropium and 100 micrograms fenoterol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (ipratropium)
Number of subjects: 22
Study: 6238551

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg and Cimetidine, 300 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 3946851

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline (10 +/- 1 mg/kg, orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30119704

Group type: EXPERIMENTAL
Intervention: Group singing intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Group creative play intervention
Number of subjects: 54
Study: 26829597

Group type: EXPERIMENTAL
Intervention: Lamotrigine augmentation therapy at 100 mg/d for subjects not taking valproate and 75 mg/d for subjects taking valproate.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lamotrigine augmentation therapy (specific doses based on valproate use).
Number of subjects: 37
Study: 24896237

Group type: EXPERIMENTAL
Intervention: Low-glycaemic index (GI) diet
Number of subjects: 372
Study: 21912843

Group type: EXPERIMENTAL
Intervention: Multi-Family Psychoeducational Psychotherapy (MF-PEP)
Number of subjects: 165
Study: 20213456

Group type: EXPERIMENTAL
Intervention: Laparoscopic VIH
Number of subjects: 146

Group type: COMPARATOR
Intervention: Open VIH
Number of subjects: 146
Study: 18564199

Group type: EXPERIMENTAL
Intervention: Serotonin-noradrenalin reuptake inhibitor (SNRI)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Last observation carried forward (LOCF)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Observed case (OC)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Mixed model for repeated measures (MMRM)
Number of subjects: 684
Study: 15929820

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 213

Group type: COMPARATOR
Intervention: Intravenous nitroglycerin
Number of subjects: 213
Study: 12802653

Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal (TAPP) repair
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open mesh repair
Number of subjects: 120
Study: 10763936

Group type: EXPERIMENTAL
Intervention: 50-Fr Maloney dilator
Number of subjects: 23

Group type: COMPARATOR
Intervention: 26-Fr Maloney dilator
Number of subjects: 23
Study: 8625713

Group type: EXPERIMENTAL
Intervention: AIDS education program (empirically based and culturally sensitive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control classes
Number of subjects: 0
Study: 1604872

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) administered as a single daily dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Divided doses of valproic acid (VPA) thrice daily
Number of subjects: 10
Study: 2857803

Group type: EXPERIMENTAL
Intervention: Aspirin 330 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dipyridamole 75 mg and Aspirin 330 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 240
Study: 30482552

Group type: EXPERIMENTAL
Intervention: Clonidine 3 μg.kg−1 with bupivacaine 0.165%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine 0.165% alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 1 μg.kg−1 with bupivacaine 0.165%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 2 μg.kg−1 with bupivacaine 0.165%
Number of subjects: 80
Study: 30342902

Group type: EXPERIMENTAL
Intervention: In-office bleaching (25% H2O2) followed by resin infiltration
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo bleaching (ACP gel) followed by resin infiltration
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (BLI and NBLI) after resin infiltration
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: BLI group after 3 months
Number of subjects: 27
Study: 27050244

Group type: EXPERIMENTAL
Intervention: 70 ml of 'BEET It Sport' nitrate shot containing 6.4 millimoles (mmol.L) or 400 mg of nitrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Blackcurrant placebo drink
Number of subjects: 12
Study: 24502856

Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 45

Group type: COMPARATOR
Intervention: Steel instruments
Number of subjects: 45
Study: 22253394

Group type: EXPERIMENTAL
Intervention: Caffeine therapy
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1640
Study: 20704115

Group type: COMPARATOR
Intervention: PFNA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Targon PF
Number of subjects: 80
Study: 17521311

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg daily for 2 weeks
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 16390760

Group type: EXPERIMENTAL
Intervention: HT + FA (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate daily and 5 mg folic acid/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HT + placebo (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 12015519

Group type: EXPERIMENTAL
Intervention: Parenteral 17beta‐estradiol (7.5 microg/24 h) delivered by a vaginal ring (Estring) for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment for 12 months
Number of subjects: 60
Study: 10725861

Group type: EXPERIMENTAL
Intervention: IDC-P subpattern A (trabecular)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IDC-P subpattern B (cribriform)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IDC-P subpattern C (solid/comedo)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Histologic criteria for IDC-P
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Immunostains for prostate-specific antigen, MUC-2, androgen receptor, and Ki-67
Number of subjects: 26
Study: 9148193

Group type: EXPERIMENTAL
Intervention: Full-vision condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-visual feedback condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No-vision 0 sec delay condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No-vision 5 sec delay condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control lines
Number of subjects: 0
Study: 1623678

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg/day for one month)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Surgical reduction of clubbed fingertips
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6202678

Group type: EXPERIMENTAL
Intervention: 800 mg subcutaneous disulfiram implant
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1200 mg subcutaneous disulfiram implant
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1600 mg subcutaneous disulfiram implant
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 31046521

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29755598

Group type: EXPERIMENTAL
Intervention: Self-authorship (SA) only
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Self-authorship with implementation intentions (SA+ii)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Active control (expert-authored messages)
Number of subjects: 62
Study: 26990867

Group type: EXPERIMENTAL
Intervention: Topical oestriol cream for 6 weeks
Number of subjects: 68
Study: 26258804

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (unsupervised session of at least 50 minutes, four times a week)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (continued physical activity as before)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Intervention group (physical activity)
Number of subjects: 151
Study: 23136215

Group type: EXPERIMENTAL
Intervention: Pneumatic compression devices (PCDs)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no PCDs)
Number of subjects: 51
Study: 21041063

Group type: EXPERIMENTAL
Intervention: Assessment of Children's Hand Skills (ACHS)
Number of subjects: 134
Study: 18304883

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study: 16931683

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (60 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 14560766

Group type: EXPERIMENTAL
Intervention: Profile-dependent support vector regression (PD-SVR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Classical multilayer perceptron (MLP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Autoregressive Conditional Heteroskedasticity (ARCH) model
Number of subjects: 110
Study: 10901475

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 242

Group type: COMPARATOR
Intervention: Pilocarpine 2% three times daily
Number of subjects: 242
Study: 9488944

Group type: EXPERIMENTAL
Intervention: THP (20 mg dissolved in 40 ml saline or 5% dextrose, administered intravesically once a week for 10 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (40 ml saline administered intravesically once a week for 10 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: THP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 8405521

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen/10 mg progestin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogen
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study: 3769774

Group type: EXPERIMENTAL
Intervention: Postcard reminder
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Telephone call reminder
Number of subjects: 311

Group type: COMPARATOR
Intervention: Monitoring for refill compliance only (Control)
Number of subjects: 311
Study: 30349198

Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 150 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 300 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 450 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 600 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 150-450 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 150-600 mg
Number of subjects: 40
Study: 27069169

Group type: EXPERIMENTAL
Intervention: Capecitabine plus Oxaliplatin (PO group)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Oxaliplatin (OX group)
Number of subjects: 169
Study: 24008819

Group type: EXPERIMENTAL
Intervention: 2-1 intramuscular (IM) regimen (group A)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Essen regimen (group B)
Number of subjects: 181
Study: 23872591

Group type: EXPERIMENTAL
Intervention: Statins plus niacin (1500 mg daily)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Statins plus placebo
Number of subjects: 145
Study: 21178911

Group type: COMPARATOR
Intervention: 7.5 mg hyperbaric bupivacaine plus 25 µg fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 7.5 mg hyperbaric levobupivacaine plus 25 µg fentanyl
Number of subjects: 60
Study: 17143000

Group type: EXPERIMENTAL
Intervention: Systemic steroid treatment (SST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonsteroid treatment (NST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study: 17078095

Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA
Number of subjects: 924

Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA and Gd‐DTPA
Number of subjects: 924
Study: 12809171

Group type: EXPERIMENTAL
Intervention: 6-month intensive medical management
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Glycemic control achieved
Number of subjects: 248

Group type: COMPARATOR
Intervention: Non-controlled subjects
Number of subjects: 248
Study: 10969306

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 50 mg hyperbaric lidocaine, 5% (n = 10)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 50 mg hyperbaric lidocaine, 5%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8985547

Group type: EXPERIMENTAL
Intervention: Otago photoscreener
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Dortmans photoscreener
Number of subjects: 113
Study: 7871905

Group type: EXPERIMENTAL
Intervention: Blocking 5-HT3 receptors with ondansetron or tropisetron-hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3340422

Group type: EXPERIMENTAL
Intervention: 1.1 micrograms/kg fentanyl (open and double-blind intravenous infusion)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Multiple random staircase (MRS) assessment method
Number of subjects: 116
Study: 29603299

Group type: EXPERIMENTAL
Intervention: One-visit root canal treatment with 2% chlorhexidine (CHX) final rinse
Number of subjects: 90

Group type: COMPARATOR
Intervention: Two-visit root canal treatment with calcium hydroxide (CH) dressing
Number of subjects: 90
Study: 28004266

Group type: EXPERIMENTAL
Intervention: Retrograde CTO-PCI
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Antegrade CTO-PCI
Number of subjects: 396

Group type: COMPARATOR
Intervention: Unsuccessful CTO-PCI
Number of subjects: 396
Study: 28302101

Group type: EXPERIMENTAL
Intervention: Culturally-grounded lifestyle intervention (weekly nutrition and wellness sessions, physical activity sessions twice a week for 6 months, followed by 3 months of booster sessions)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 24067873

Group type: EXPERIMENTAL
Intervention: Hemiplegic shoulder pain
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adhesive capsulitis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 14
Study: 21415398

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection(s) plus a 4‐week therapy program
Number of subjects: 333

Group type: COMPARATOR
Intervention: Therapy program alone
Number of subjects: 333
Study: 19373973

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 590

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 590
Study: 18075401

Group type: EXPERIMENTAL
Intervention: 1-g EMLA cream applied 1 hour before the procedure
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo cream applied 1 hour before the procedure
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1-g EMLA cream
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 52
Study: 14746532

Group type: EXPERIMENTAL
Intervention: Rituximab (Rituxan®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab (MabThera®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab in combination with standard chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study: 11683282

Group type: EXPERIMENTAL
Intervention: Subcutaneous curettage
Number of subjects: 113

Group type: COMPARATOR
Intervention: Injection of botulinum toxin A (BT-A)
Number of subjects: 113
Study: 9564467

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0
Study: 7797926

Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule (A; days 0, 10, 21)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Classic vaccination schedule (C; days 0, 28, 56)
Number of subjects: 270
Study: 2204594

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside and doxorubicin combined with etoposide (CTR III)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside and doxorubicin combined with 6-thioguanine (DAT)
Number of subjects: 72
Study: 625462

Group type: EXPERIMENTAL
Intervention: Unrefined wheat diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rice diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Varied rice diet (from another area)
Number of subjects: 42
Study: 31229528

Group type: COMPARATOR
Intervention: Physical activity plus fatigue self-management intervention (FM+)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Physical activity-only intervention (PA-only)
Number of subjects: 208
Study: 29806427

Group type: EXPERIMENTAL
Intervention: Three-dimensional strapping reduction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Towel clamp reduction
Number of subjects: 32
Study: 26124084

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy (75mg/m2 docetaxel d1, 75mg/m2 cisplatin d1, and 750mg/m2/day 5‐fluorouracil d1‐5) followed by radical surgery and post‐operative radiotherapy
Number of subjects: 256

Group type: COMPARATOR
Intervention: Upfront radical surgery and post‐operative radiotherapy
Number of subjects: 256
Study: 23404203

Group type: EXPERIMENTAL
Intervention: Peer health coaching
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study: 22025880

Group type: EXPERIMENTAL
Intervention: Probiotic goat yogurt with 10(9) CFU/mL Bifidobacterium longum
Number of subjects: 59

Group type: COMPARATOR
Intervention: Formula yogurt (without probiotics)
Number of subjects: 59
Study: 18481713

Group type: EXPERIMENTAL
Intervention: Acupuncture at 3-5 of the most severe tender points
Number of subjects: 66

Group type: COMPARATOR
Intervention: Medication group (oral administration according to WHO Three Step Administration Principle: aspirin for mild pain, codeine for moderate pain, morphine for severe pain)
Number of subjects: 66
Study: 16816757

Group type: EXPERIMENTAL
Intervention: Continuous epidural ropivacaine 0.3%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous intravenous morphine
Number of subjects: 30
Study: 14579873

Group type: EXPERIMENTAL
Intervention: Prototype power toothbrush (Crest SpinBrush Pro)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control manual toothbrush (Oral-B Cross Action)
Number of subjects: 40
Study: 10763793

Group type: EXPERIMENTAL
Intervention: Specialist nurse interventions including information, advice, support, and monitoring
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Collaboration with 17 other professional groups
Number of subjects: 101
Study: 1953532

Group type: EXPERIMENTAL
Intervention: Oral vaccine containing killed Haemophilus influenzae
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 7447203

Group type: EXPERIMENTAL
Intervention: Low-dose verapamil (0.075 mg/kg body weight)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-dose verapamil (0.15 mg/kg body weight)
Number of subjects: 50
Study: 31502906

Group type: COMPARATOR
Intervention: Enhanced Screening and Referral (ESR)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Personalized Support for Progress (PSP)
Number of subjects: 235
Study: 30448451

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) once-daily (OD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar) U100 + insulin aspart (IAsp) once-daily (OD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 0

Group type: COMPARATOR
Intervention: IGlar U100 + IAsp
Number of subjects: 0
Study: 29482955

Group type: EXPERIMENTAL
Intervention: Removable orthosis
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Nonremovable orthosis
Number of subjects: 249

Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 249
Study: 26896686

Group type: EXPERIMENTAL
Intervention: Cervarix™ HPV vaccine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Gardasil™ HPV vaccine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 91
Study: 24502766

Group type: EXPERIMENTAL
Intervention: Dietary arginine supplementation (0% vs. 1%)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Reduced protein diet (RPD)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Leucine supplementation of RPD
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal protein diet (NPD)
Number of subjects: 54